THE AIMS OF ANTIPSYCHOTIC MEDICATION - WHAT ARE THEY AND ARE THEY BEING ACHIEVED

Citation
Ag. Awad et al., THE AIMS OF ANTIPSYCHOTIC MEDICATION - WHAT ARE THEY AND ARE THEY BEING ACHIEVED, CNS DRUGS, 4(1), 1995, pp. 8-16
Citations number
47
Categorie Soggetti
Neurosciences,"Pharmacology & Pharmacy
Journal title
ISSN journal
11727047
Volume
4
Issue
1
Year of publication
1995
Pages
8 - 16
Database
ISI
SICI code
1172-7047(1995)4:1<8:TAOAM->2.0.ZU;2-4
Abstract
The aims of therapy with antipsychotic medications include effective r elief of symptoms without the induction of adverse effects, improved q uality of life and cost effectiveness, and positive long term outcomes . However, currently available antipsychotics do not meet all of these requirements due to a number of well recognised limitations, such as a marked variability of response, induction of a wide range of adverse effects and a lack of subjective tolerability. A lack of response to antipsychotic medications occurs in up to 30% of patients and poses a particular challenge to clinicians. The reintroduction of clozapine fo r the treatment of patients with refractory schizophrenia has proven u seful in a good number of patients, albeit with some risk of serious a granulocytosis and at a relatively high cost. Despite the extensive us e of antipsychotics over the last 4 decades, Little attention has been paid to the systematic evaluation of quality of life in patients with schizophrenia who receive medications, and in clinical trials of new agents. Similarly, there is a dearth of studies that have examined the cost effectiveness and cost utility of antipsychotics in terms of qua lity of life. In general, the aim of antipsychotics of alleviating psy chotic symptoms without negatively affecting the functional status of patients has not been adequately, nor consistently, achieved with curr ently available agents. However, with the recent acceleration in the d evelopment of new antipsychotics, it is hoped that new drugs will soon be available which will prove to be more effective in treating more s ymptoms of schizophrenia and will be associated with fewer, or ideally no, adverse effects.